BioSpace News Archive

Innovent Biologics, Inc. announced that the final analysis results of ORIENT-15, the Phase 3 study evaluating sintilimab in combination with chemotherapy for the first-line treatment of esophageal squamous cell carcinoma were released in a poster presentation at the American Association for Cancer Research Annual Meeting 2023.

Abbisko announced the results of five latest preclinical studies at the 2023 American Association for Cancer Research annual meeting.

Accent Therapeutics presented data supporting DHX9 inhibition as a novel cancer treatment approach at the American Association for Cancer Research Annual Meeting 2023 in Orlando, Florida.

Satsuma Pharmaceuticals, Inc. announced that it has entered into a definitive agreement to be acquired by Shin Nippon Biomedical Laboratories, Ltd. for $0.91 in cash per share at the closing of the transaction plus one non-tradeable contingent value right of up to $5.77 per share.

Merck, known as MSD outside of the United States and Canada, announced results from the Phase 3 KEYNOTE-966 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with standard of care chemotherapy for the first-line treatment of patients with advanced or unresectable biliary tract cancer.

Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, provided the final results from its phase 2 REDIRECT study investigating its innate cell engager AFM13 monotherapy in patients with heavily pretreated advanced-stage r/r PTCL.

Telix Pharmaceuticals Limited announces successful preclinical development of radiolabelled olaratumab, an antibody licensed from Eli Lilly and Company.

MorphoSys U.S. Inc., a fully owned subsidiary of MorphoSys AG, and Incyte announced final five-year follow-up data from the Phase 2 L-MIND study showing that Monjuvi® plus lenalidomide followed by Monjuvi monotherapy provided prolonged, durable responses in adult patients with relapsed or refractory diffuse large B-cell lymphoma.

Vaxcyte, Inc. announced it will hold a webcast and conference call tomorrow, April 17, 2023, at 7:30 a.m. Eastern Time to discuss results from the Phase 2 study of VAX-24, the Company’s lead, broad-spectrum 24-valent pneumococcal conjugate vaccine candidate, in adults aged 65 and older and full six-month safety data from both adult Phase 2 studies.

As a global innovative biopharmaceutical company, Henlius is committed to offering high-quality, affordable and innovative biopharmaceuticals to patients worldwide with 5 products launched in China.